Name : Cynomolgus Tim-3/HAVCR2 Protein
Product Source :
Recombinant Cynomolgus Tim-3/HAVCR2 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Ser22-Arg201.[Accession | EHH54703.1]
Molecular Weight :
The protein has a predicted MW of 20.8 kDa. Due to glycosylation, the protein migrates to 45-55 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Cynomolgus Tim-3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. ELISA Data Immobilized Cynomolgus TIM-3, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-TIM-3 Antibody, hFc Tag with the EC50 of 25.9ng/ml determined by ELISA.
Background :
Hepatitis A virus cellular receptor 2 (HAVCR2), also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), is a protein that in humans is encoded by the HAVCR2 gene.TIM3 is an immune checkpoint and together with other inhibitory receptors including programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3) mediate the CD8 T-cell exhaustion. TIM3 has also been shown as a CD4 Th1-specific cell surface protein that regulates macrophage activation and enhances the severity of experimental autoimmune encephalomyelitis in mice.
Synonyms :
CD366; TIM3; TIM-3; TIMD-3; TIM 3; FLJ14428; HAVCR2; KIM3
References & Citations :
(1)Wenwen D , Min Y , Abbey T , et al. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action[J]. International Journal of Molecular Sciences, 2017, 18(3):645-.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
TPST1 ProteinPurity & Documentation
HLA-AFormulation
Popular categories:
EphB1
CD40 Ligand